
CASI Pharmaceuticals, Inc. Ordinary Shares
CASI
CASI: CASI Pharmaceuticals Inc is a biopharmaceutical company that focuses on commercializing innovative therapeutics and pharmaceutical products. The products include injections for patients who are suffering from leukemias and lymphomas. The EVOMELA injection is used as a conditioning treatment before autologous stem cell transplant for patients with multiple myeloma. The company products include CID-103, CNCT19, EVOMELA, MARQIBO, ZEVALIN, ENMD-2076 and others. The majority of the revenue is generated from the product sales of EVOMELA. The company primarily operates in the United States, Canada, China and other parts of the world.
moreShow CASI Financials
Recent trades of CASI by members of U.S. Congress
Recently reported changes by institutional investors
Quarterly net insider trading by CASI's directors and management
Government lobbying spending instances
New patents grants
-
Patent Title: Method for the treatment of multiple sclerosis Sep. 15, 2015
Federal grants, loans, and purchases
Followers on CASI's company Twitter account
Number of mentions of CASI in WallStreetBets Daily Discussion
Recent insights relating to CASI
Recent picks made for CASI stock on CNBC
ETFs with the largest estimated holdings in CASI
Flights by private jets registered to CASI